To include your compound in the COVID-19 Resource Center, submit it here.

Analyst picks & changes

Gensia Inc.

(GNSA)

Richard Stover of Stover Haley Burns said he remains optimistic regarding the regulatory review of GNSA's Protara (Arasine), despite the company's announcement earlier this month that the FDA won't review the drug for reducing

Read the full 374 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE